Unintentional exposure to leuprolide acetate during early pregnancy with a huge intramural myoma
Issued Date
2025-01-02
Resource Type
eISSN
1757790X
Scopus ID
2-s2.0-85214590001
Pubmed ID
39753288
Journal Title
BMJ case reports
Volume
18
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
BMJ case reports Vol.18 No.1 (2025)
Suggested Citation
Nuchpramool P., Thanapongpibul C., Siriprapaphan R., Kulthamrongsri N. Unintentional exposure to leuprolide acetate during early pregnancy with a huge intramural myoma. BMJ case reports Vol.18 No.1 (2025). doi:10.1136/bcr-2024-262211 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/102882
Title
Unintentional exposure to leuprolide acetate during early pregnancy with a huge intramural myoma
Corresponding Author(s)
Other Contributor(s)
Abstract
Leuprolide acetate is commonly used to reduce the size of myomas before surgery. Initially, it stimulates pituitary gonadotropin secretion, followed by sustained suppression of gonadal function. However, the impact on pregnancy outcomes from inadvertent exposure remains unclear. This case involves a woman in her 30s, multiparous, with a 20-week-sized leiomyoma, who received two doses of 3.75 mg subcutaneous leuprolide acetate, 15 days after menstruation, 4 weeks apart. An ultrasound, conducted 2 weeks after the last dose, accidentally revealed a viable intrauterine pregnancy at 8+6 weeks gestation. Her pregnancy progressed without complications, culminating in a term caesarean delivery without fetal anomalies. She opted for a total hysterectomy with bilateral salpingectomy 6 months later. Despite unclear teratogenic effects, evidence suggests that leuprolide acetate does not significantly impact pregnancy outcomes.